Are WHO approved nucleic acid amplification tests causing large-scale “false identification” of rifampicin-resistant tuberculosis?: Programmatic experience from south india | Zendy

Praveen Sanker | Zendy; AnusreeP Ambika | Zendy; VishnuT Santhosh | Zendy; RamyaPuthukkudi Kottuthodi | Zendy; Ravikrishnan Balakrishnan | Zendy; SunilKumar Mrithunjayan | Zendy; Hisham Moosan | Zendy

Open Access

Are WHO approved nucleic acid amplification tests causing large-scale “false identification” of rifampicin-resistant tuberculosis?: Programmatic experience from south india

Author(s) -

Praveen Sanker,

AnusreeP Ambika,

VishnuT Santhosh,

RamyaPuthukkudi Kottuthodi,

Ravikrishnan Balakrishnan,

SunilKumar Mrithunjayan,

Hisham Moosan

Publication year - 2017

Publication title -

international journal of mycobacteriology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.53

H-Index - 20

eISSN - 2212-554X

pISSN - 2212-5531

DOI - 10.4103/2212-5531.201900

Subject(s) - nucleic acid amplification tests , genexpert mtb/rif , tuberculosis , medicine , rifampicin , tuberculosis control , breakpoint , sputum , virology , biology , pathology , genetics , gene , chromosomal translocation , chlamydia trachomatis

The nucleic acid amplification tests (NAATs): Line probe assay and GeneXpert (Xpert) have evolved as the primary tool for identification of rifampicin (RIF)-resistant (RR) tuberculosis (TB) worldwide, primarily because of the ease and speed. We rechecked RR isolates identified by NAATs from presumptive RR TB cases belonging to South India by the Revised National TB Control Program, India using multiple RIF concentrations on Bactec MGIT system and compared the mutation patterns with the resistance levels.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research